Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy
Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy
复制标题
DOI：
10.1016/s0959-8049(03)00675-0
复制
发表时间：
2004-01-01
影响因子：
8.4
通讯作者：
Ghnassia, JP
中科院分区：
文献类型：
--
作者：
Petit, T;Wilt, M;Ghnassia, JP
本研究的目的是评估5种不同的生物学因素对接受新辅助蒽环类药物化疗的乳腺癌患者的预测价值：（1）根据Elston-Ellis分类进行的肿瘤分级，（2）激素受体（HR）状态;（3）通过Ki-67染色评价的肿瘤细胞增殖，（4）HER-2和拓扑异构酶11 α（5）HER-2和TopoII α扩增通过实时聚合酶链反应（PCR）评估。119例可手术乳腺癌患者采用FEC方案（5-氟尿嘧啶（5-FU）100 mg/m2，依匹罗林100 mg/m2，环磷酰胺500 mg/m2）治疗6个周期。通过临床和计算机断层扫描（CT）评估肿瘤缓解，然后进行病理评估。临床总缓解率（OR）为80%，完全缓解率（CR）为19%。放射学OR为71%，CR为16%。根据Sataloff分类，13%的患者表现出病理性CR。在多变量分析中，HR表达缺失和Ki-67 ≥ 20%可预测临床CR。高肿瘤分级可预测病理性CR。HER 2或Topollcalpha的过表达或扩增不能预测缓解。(C)2003 Elsevier Ltd.保留所有权利。
The aim of this study was to evaluate the predictive value of five different biological factors in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy: (1) tumour grade scored according to the Elston-Ellis classification, (2) hormonal receptor (HR) status; (3) tumour cell proliferation evaluated by Ki-67 staining, (4) HER-2 and topoisomerase 11 alpha (TopoIIalpha) expression evaluated by immunohistochemistry (IHC), (5) HER-2 and TopoIIalpha amplification evaluated by real-time polymerase chain reaction (PCR). 119 patients with operable breast cancer were treated with six cycles of FEC (100 5-fluorouracil (5-FU) 500 mg/m(2), Epirubicin 100 mg/m(2), Cyclophosphamide 500 mg/m(2)). Tumour response was assessed clinically and by computed tomography (CT) scan, then by pathological assessment. The clinical overall response (OR) was 80%, with 19% of complete responders (CR). The radiological OR was 71%, with 16% of CR. A pathological CR was demonstrated in 13% of the patients according to the Sataloff classification. In the multivariate analysis, the absence of HR expression and Ki-67 greater than or equal to 20% were predictive for a clinical CR. A high tumour grade was predictive for a pathological CR. Overexpression or amplification of HER2 or Topollcalpha were not predictive of response. (C) 2003 Elsevier Ltd. All rights reserved.